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Sinoatrial cell modelLower heart rate is associated with better survival in patients with multiple organ dysfunction syndrome
(MODS), a disease mostly caused by sepsis. The beneﬁts of heart rate reduction by ivabradine during MODS
are currently being investigated in the MODIfY clinical trial. Ivabradine is a selective inhibitor of the pacemaker
current If and since If is impaired by lipopolysaccharide (LPS, endotoxin), a trigger of sepsis,we aimed to explore If
blocking potency of ivabradine under elevated endotoxin levels in human atrial cardiomyocytes. Treatment of
myocytes with S-LPS (containing the lipid A moiety, a core oligosaccharide and an O-polysaccharide chain)
but not R595 (an O-chain lacking LPS-form) caused If inhibition under acute and chronic septic conditions. The
speciﬁc interaction of S-LPS but not R595 to pacemaker channels HCN2 and HCN4 proves the necessity of O-
chain for S-LPS–HCN interaction. The efﬁcacy of ivabradine to block If was reduced under septic conditions, an
observation that correlated with lower intracellular ivabradine concentrations in S-LPS- but not R595-treated
cardiomyocytes. Computational analysis using a sinoatrial pacemaker cellmodel revealed that despite a reduction
of If under septic conditions, ivabradine further decelerated pacemaking activity. This novelﬁnding, i.e. If inhibition
by ivabradine under elevated endotoxin levels in vitro, may provide a molecular understanding for the efﬁcacy of
this drug on heart rate reduction under septic conditions in vivo, e.g. the MODIfY clinical trial.
© 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Sepsis, a microbial induced inﬂammatory response, encompasses a
spectrum of illness that ranges from systemic infection to multiple
organ dysfunction syndrome (MODS) [1]. Mortality due to septic
cardiac dysfunction has been encountered in critically ill patients [2]
where an increased heart rate may act as an independent risk factor
[3]. Patients with lower heart rate in the early phase of MODS have
better survival rates than those with higher heart rate [3].
Sepsis is induced by lipopolysaccharide (LPS, endotoxin), a major
component of the outer cell wall of gram-negative bacteria. Notably,
LPS from wild type bacteria usually is a mix of S-form LPS and varying
proportions of so-called R-form LPS [4]. S-form LPS consists of three
entities: the lipid A moiety, that harbours the endotoxic activity of the
entire molecule, the core oligosaccharide and the O-polysaccharide
chain, that is absent in R-form LPS [5,6]. Irrespective of their structural+43 316 380 9660.
Zorn-Pauly),
. This is an open access article undercomponents, both LPS forms are capable to initiate sepsis by triggering
the inﬂammatory response [7]. Besides initiating the inﬂammatory
response, S-form LPS directly affects ionic channels of immune, neu-
ronal and cardiovascular cells [8–10], the latter include channels
conducting the pacemaker current If. This current is amixedNa+/K+ in-
ward current carried by pacemaker channels comprising four different
homo- or heteromeric isoforms of hyperpolarization-activated cyclic
nucleotide-gated (HCN 1–4) channels [11]. If plays an important role
in the regulation of heart rate [12] by contributing to the slow diastolic
depolarization phase that determines the ﬁring rate of spontaneous
action potentials of sinoatrial node cells [13]. Moreover, in response to
autonomic transmitters, If contributes to the chronotropic regulation of
heart rate [13]. Previously, we reported If loss-of-function in human atri-
al myocytes after chronic S-LPS treatment, an observation that in turn
might be responsible for reduction of heart rate variability during sepsis
[14,15]. Meanwhile it was shown that S-form LPS also acutely impairs If
[16,17] and that the polysaccharide part (O-chain) of the LPS molecule
[16] is necessary for reduction of pacemaker channel activity.
Beta-blocker administration has been shown to reduce mortality in
MODS [18,19]. However, negative inotropic effects of beta-blockersthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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considered as an alternative therapeutic approach to reduce heart rate.
This drug is a pure heart rate lowering agent that selectively inhibits If
[20]. Ivabradine blocks pacemaker channels in a use-dependent way
beingmore effective at higher heart ratewhile its action declines during
bradycardia [21,22]. Blocking of pacemaker channels by ivabradine re-
quires three steps: diffusion through the cell membrane, opening of re-
spective channels and intracellular binding of the drug to the channel
pore [20,23]. Heart rate reductionby ivabradine has been found to be ben-
eﬁcial in the treatment of cardiovascular disease, since it lowers heart rate
without adversely affecting other cardiovascular functions [24].
Currently, the MODIfY trial carefully investigates potential beneﬁts
of heart rate reduction by ivabradine in sepsis and MODS [19]. Since
S-LPS substantially inhibits If and ivabradine is administered in septic
patients (MODIfY trial), we hypothesized that If reduction by S-LPS
might interfere with ivabradine action on If. From a clinical perspective,
the efﬁcacy of If inhibition by ivabradine under septic conditions is of
special therapeutic relevance.
In this study we investigated the effect of S-LPS and R595 on
human atrial If under acute and chronic septic conditions as well as
the interaction of both endotoxins with HCN channels. Next, we
focused on the effect of endotoxins on (i) If reduction by ivabradineFig. 1. Representative pacemaker current recordings of human atrial myocytes. Pacemaker curr
(10 mV increment, holding potential−40mV, 3 s duration) and normalized to cell capacitance
(7 min) (B), S-LPS (6 h) (C) or R595 (6 h) (D). Arrows indicate current at−70 mV.and (ii) intracellular ivabradine concentrations. Finally, using a com-
puter simulation model we tried to explore the efﬁcacy of ivabradine
on deceleration of sinoatrial pacemaking activity under septic
conditions.
2. Material and methods
A detailed Materials and methods section on isolation of
cardiomyocytes [25–27], cell culture [28], myocyte treatments,
patch-clamp measurements [14,29,30], immunoprecipitation [31],
Western blot and immuno-dot-blot [32], qPCR [33], determination of
ivabradine concentrations by HPLC [34] and sinoatrial pacemaker cell
modeling [35] is available under the online supplemental section.
3. Results
3.1. Representative recordings of If of human atrial myocytes
Fig. 1 shows representative traces of If under control (Fig. 1A),
ivabradine (Fig. 1B) and septic conditions (mimicked in vitro by LPS
incubation, Figs. 1C and D) elicited by hyperpolarizing voltage steps
from−40 to−130 mV. If was considered to be present when currentents (pA) were recorded by hyperpolarizing voltage steps ranging from−40 to−130mV
(pF) for a control cell (A) and for cells treatedwith indicated concentrations of ivabradine
66 S. Scheruebel et al. / Journal of Molecular and Cellular Cardiology 72 (2014) 64–73density was higher than 0.5 pA/pF at−120 mV; this was the case in
about 90% of all tested human atrialmyocytes. The prominent reduction
of If by ivabradine (Fig. 1B) reveals the heart rate lowering potency of
this drug [36]. Under septic conditions only S-LPS (Fig. 1C) but not
R595 (Fig. 1D) caused a more negative If activation threshold (control:
between−60 and−70 mV, S-LPS: between−70 and−80 mV; note
the arrows indicating current at−70 mV). Irrespective of their origin,
both S-LPS preparations (extracted from either Escherichia coli or
Salmonella enterica serotypeMinnesota) had an almost identical effect
on If steady-state activation (Supplemental Fig. S1).3.2. Effect of endotoxins on If of human atrial myocytes
In order to investigate If under acute application of endotoxins, cells
were superfused (6 min) with either S-LPS or R595. Fig. 2A shows
representative pacemaker current recordings at indicated membrane
potentials before and after S-LPS superfusion. S-LPS treatment resulted
in a signiﬁcant (i) reduction of If between −60 and −130 mV
(Fig. 2B), (ii) shift of steady-state activation of If towards more negative
membrane potentials (Fig. 2C) and (iii) slowing down of If current acti-
vation (Fig. 2D). The maximal If reduction by S-LPS occurred between 3
and 4 min (Fig. 2E) and was signiﬁcantly more pronounced than the
time-dependent If rundown (see also Supplemental Fig. S2). In line
with a recent study where R595 had no acute effects on HCN2 current
[16], we also did not observe any R595-mediated acute effects on If in
human cardiomyocytes (data not shown).Fig. 2. Acute effects of S-LPS on pacemaker current of human atrial myocytes. (A) Representativ
6 min). (B) I–V relationships of If before and after S-LPS superfusion. (C) If steady-state activatio
function. Control: V1/2=−85.4 ± 3.0 mV, k=8.8± 0.8mV; LPS: V1/2 =−98.0± 3.1mV, k=
Values were obtained by ﬁtting a monoexponential function to current traces. (E) Time-depend
were applied to−80mV for 3 s from a holding potential of−40mV (1/30Hz, 8 min). Measure
*p ≤ 0.05 vs. control.In order to investigate If under chronic conditions, myocytes were
incubatedwith endotoxins for 6–10 h. In linewith our previous ﬁndings
[14] S-LPS shifted If steady-state activation towards more negative
membrane potentials, slowed down its current activation (data not
shown) and signiﬁcantly reduced current density at −70 and
−80 mV. In contrast to S-LPS, R595 did neither reduce If (Fig. 3A) nor
alter If steady-state activation or time constants of If activation
compared to controls (Figs. 3B and C).3.3. Interactions of endotoxins with HCN channels
Acute S-LPS perfusion rapidly decreased If in human cardiomyocytes
(Fig. 2E). Furthermore, S-LPS superfusion of HEK293 cells overexpress-
ing HCN2 (themajor isoform expressed in human atrial myocytes [37])
was found to reduce If by approx. 30% within 8 s [16]. These observa-
tions suggest a direct interaction of S-LPS with HCN channels. In order
to test this hypothesis, a series of dot-blot experiments was performed.
S-LPS and R595 preparations were cross-linked to activated
(prewetted) PVDF membranes. After drying (inactivation) the mem-
branes were incubated with either HCN2 or HCN4 (the major isoform
in sinoatrial node cells [38]) that had been immunoprecipitated
from murine heart (Supplemental Fig. S3). Using speciﬁc antibodies
to follow endotoxin–HCN interactions, immunoreactive signals for
HCN2 (Fig. 4A [2a, 3a]) and HCN4 (Supplemental Fig. S4) could
only be detected with S-LPS (but not R595) cross-linkedmembranes.
Observations that S-LPS and R595 interact with HDL/apoA-I (thee superimposed current recordings of a cell before and after S-LPS superfusion (10 μg/mL,
n before and after S-LPS superfusion. Normalized conductanceswere ﬁtted by a Boltzmann
6.3 ± 0.4 mV. (D)Mean time constants of If activation before and after S-LPS superfusion.
ent current reduction of If by S-LPS and under control conditions. Repetitive voltage steps
ments were normalized to initial values and reduction of current densities was calculated.
Fig. 3. Chronic effects of S-LPS and R595 on pacemaker current of human atrial myocytes. Cells were incubated with S-LPS or R595 (10 μg/mL, 6–10 h. (A) Mean I–V relationships
of If in control and endotoxin-treated cells. (B) If steady-state activation for control and R595-treated cells. Normalized conductances were ﬁtted by a Boltzmann function.
Control: V1/2 = −83.3 ± 1.2 mV, k = 7.8 ± 0.4 mV; R595: V1/2 = −80.3 ± 1.3 mV, k = 7.0 ± 0.5 mV. (C) Mean time constants of If activation for control and R595-treated
cells. Values were obtained by ﬁtting a monoexponential function to current traces. +p ≤ 0.05 vs. control and R595; §p ≤ 0.05 vs. R595.
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LPS preparations [39], conﬁrm the capacity of both endotoxin prepa-
rations to interact with candidate ligands. To further validate our
ﬁndings, endotoxin-cross-linked membranes were incubated with
murine total IgG, being present in immunoprecipitated HCN2; the
lack of immunoreactivity (Fig. 4A [5a]) conﬁrmed that the observed
S-LPS–HCN2 interaction is speciﬁc and not due to S-LPS–IgG interac-
tion. In addition, no immunoreactive signals were observed when
inactivated membranes were incubated with either HCN2 or HDL
(Fig. 4A [2b, 3b, 4b]), while incubation of HCN2 or HDL to activated
membranes showed immunoreactivity (Fig. 4A [3c, 4c]). These neg-
ative and positive controls further conﬁrm the speciﬁcity of S-LPS–
HCN channel interaction.
As immunoprecipitated HCN2 and HCN4 were denatured by LDS
sample buffer, the unspeciﬁc interaction of S-LPS with unfolded
channel might have occurred. To show that also non-denatured
HCN2 and HCN4 channels interact with endotoxins, cross-linked
membranes were incubated with murine heart protein lysates;
these experiments conﬁrm interaction of intact HCN2 and HCN4
channels to S-LPS but not R595 (data not shown).If is impaired in a similar manner under acute (Fig. 2B) and chron-
ic S-LPS conditions (Fig. 3A) and S-LPS interacts with both HCN chan-
nel isoforms (Fig. 4A, Supplemental Fig. S4). To gain insights whether
chronic endotoxin treatment could modulate channel expression,
HL-1 cells (where If reduction after S-LPS treatment was previously
reported [40]) were used. Both endotoxins did not alter mRNA
(HCN2 and HCN4, up to 24 h) or protein expression (HCN2, 6 and
24 h); only the 6 h time point is shown (Fig. 4B, a/b).
3.4. Effect of ivabradine on If of human atrial myocytes
Fig. 5A shows the effect of ivabradine on If elicited by protocol 1 (p1,
see inset) before and after ivabradine superfusion of cardiomyocytes. A
use-dependent If block by ivabradine was established by protocol 2 (p2,
see inset). Ivabradine signiﬁcantly reduced If (from−80 to−130 mV)
but did not change steady-state (Fig. 5B) or time constants of If activa-
tion (Fig. 5C). A current rundownwas observed after stimulation of con-
trol cardiomyocytes using protocol p2. Ivabradine-induced If reduction
(dark grey bars)was signiﬁcantly higher compared to current rundown
in controls (white bars) at all given membrane potentials (Fig. 6D).
Fig. 4. LPS–HCN interactions. (A)Dot-blot analysis for LPS–HCN2binding. a: S-LPS andR595
(10 μg) were cross-linked with methanol prewetted PVDF membranes. Membranes were
dried and dots were incubated with PBS (1a), indicated volumes of immunoprecipitated
HCN2 protein (2a/3a), HDL (4a) or puriﬁedmurine total IgG (5a). b: Prewetted PVDFmem-
branes were dried followed by dotting with immunoprecipitated HCN2 protein (2b/3b) or
HDL (4b). c: Immunoprecipitated HCN2 protein (3c) or HDL (4c) was dotted onto
prewetted membranes. After all incubation steps lanes 1–5 were incubated with indicated
primary antibody and immunoreactive dots were visualized; empty circles represent
no immunoreactivity. One representative experiment out of 3 is shown. (B) mRNA
(a, n = 8) and protein expression (b, one representative experiment out of 3 is
shown) of HCN isoforms after S-LPS or R595 treatment (10 μg/mL, 6 h) in HL-1
cells using qPCR and Western blot, respectively.
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septic conditions
Ivabradine treatment signiﬁcantly reduced If at membrane poten-
tials from −90 to −130 mV in both S-LPS- and R595-incubated
cardiomyocytes (Figs. 6A and B). The signiﬁcantly reduced If current
density at a membrane potential of −80 mV in R595 incubated cells
(Fig. 6B) did not differ from current rundown (Fig. 6D).
Fig. 6C shows the time-dependent development of ivabradine in-
duced If blockage in control and S-LPS/R595 incubated cells at a mem-
brane potential of −100 mV (protocol p2, see inset Fig. 5A). In order
to calculate If reduction ﬁve consecutive measurements of current den-
sities during a 30 s period were averaged and normalized to initial
values. If blockage by ivabradine was signiﬁcantly higher in controls
than in endotoxin incubated cells but did not differ between the two
LPS forms. Furthermore, current rundown in control cardiomyocytes
(beginning 2.5 min after protocol p2 had been started) was signiﬁcantly
smaller than If reduction in all ivabradine-treated cardiomyocytes.Fig. 6D shows that the efﬁcacy of ivabradine to block If is signiﬁcantly
reduced in endotoxin incubated myocytes over a wide membrane
potential range. If reduction was calculated from the underlying I–V re-
lationships before and after ivabradine superfusion.
If steady-state activation (which is shifted towards more negative
membrane potentials by S-LPS but not R595) was not further affected
by ivabradine in endotoxin-treated myocytes (data not shown).
3.6. Effect of endotoxins on intracellular ivabradine concentrations in
guinea pig ventricular myocytes
Under septic conditions If inhibition by ivabradine is reduced com-
pared to controls (Figs. 6C and D). Since ivabradine diffuses across the
cell membrane [23] and S-LPS is known to change cell membrane integ-
rity [41], a reduction in intracellular ivabradine concentrations in endo-
toxin incubated myocytes might be the consequence. To test this
hypothesis, intracellular ivabradine concentrations were measured in
guinea pig cardiomyocytes due to the limited yield of humanmyocytes.
Representative HPLC-chromatograms are shown in Fig. 7A. Intracellular
ivabradine concentrations ranged between 1.55 and 3.31 pmoL/mg
total cell protein in different control myocyte preparations. From
Fig. 7B, it is evident that incubation of cells with S-LPS (but not R595)
signiﬁcantly reduced intracellular ivabradine concentrations compared
to respective controls.
3.7. Effect of ivabradine on sinoatrial pacemaking activity in the presence of
S-LPS: a computer simulation model
To gain ﬁrst indications whether an impaired If (by S-LPS) is still a
suitable target for ivabradine to reduce sinoatrial beating rate, experi-
mental data were implemented in a sinoatrial computer cell model
[35]. Based on our present and previously reported [14] experimental
data using human myocytes, the effect of S-LPS was implemented in
the model as an If V1/2 shift of−14 mV (which represents a shift of If
V1/2 in the sinoatrial cell model from−52.5 to−66.5 mV). The action
of ivabradine was simulated by reduction of If conductance (66% and
35% in control and S-LPS incubated cells, respectively; see Figs. 5A and
6A).
In this simulation model, ivabradine (open squares) reduced If at all
membrane potentials, while S-LPS (ﬁlled circles) had a reducing effect
on If between −50 and−100 mV (Fig. 8A). At membrane potentials
positive to approximately−65mV, If reduction by S-LPSwasmore pro-
nounced compared to ivabradine. Combining effects of both com-
pounds, the most prominent decrease of If between −40 and
−70 mV became apparent (grey diamonds). The gradual decrease of If
at physiologically relevant membrane potentials (Fig. 8A) resulted in a
gradual increase in cycle length (CL) from 355 ms (controls (1)) to
455 ms (ivabradine (2)), 569 ms (S-LPS (3)) and 604 ms (S-LPS and
ivabradine (4), Fig. 8B). A systematic variation of the two If model pa-
rameters (Fig. 8C) predicts that CL is more strongly inﬂuenced by an If
V1/2 shift (to more negative membrane potentials) than by reduction
of If conductance. For example, CL alteration by an If V1/2 shift of only
−2 mV is equivalent to a 20% decrease in If conductance. Moreover,
the simulation model clearly shows that at all given V1/2 values (shifted
by S-LPS), a reduction of If conductance due to ivabradine treatment
leads to an additional decrease in CL. In conclusion, ivabradine is
efﬁcient to decelerate sinoatrial pacemaking activity in silico in the
presence of S-LPS.
4. Discussion
Sepsis and sepsis induced MODS are considered as highly complex
diseases where heart pacemaking function is expected to bemodulated
by direct and indirect endotoxin effects [15,42]. In the present study, we
exclusively focused on the direct effects of endotoxin on human atrial
pacemaker current (If). We here report that S-LPS exerts besides a
Fig. 5. Effect of ivabradine on pacemaker current of human atrial myocytes. (A) Mean I–V relationships of If before and after ivabradine superfusion (1 μmol/L, 7 min). Inset
shows the voltage clamp protocol. (B) If steady-state activation in control and ivabradine superfused cells. Normalized conductances were ﬁtted by a Boltzmann function.
Control: V1/2 =−83.3 ± 1.2 mV, k= 7.8 ± 0.4 mV; ivabradine: V1/2 =−84.1 ± 4.0 mV, k= 7.9 ± 2.5 mV. (C) Mean time constants of If activation before and after ivabradine
superfusion. Values were obtained by ﬁtting a monoexponential function to current traces. *p ≤ 0.05 vs. control.
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explanation for S-LPS-induced impairment of If, namely the interaction
of the O-chain of S-LPS to the HCN channel. Furthermore, we explored
the effect of ivabradine on If under septic conditions. To our knowledge,
we are the ﬁrst to show that the inhibitory action of ivabradine on If is
reduced under elevated endotoxin concentrations. However, our in
silico results show that the efﬁcacy of ivabradine to decelerate pacemak-
ing activity is preserved under septic conditions.
Previously we have reported If impairment in human myocytes
under chronic S-LPS conditions [14]. We now report reduction of If by
S-LPS (but not R595) under acute conditions. The data are in line with
ﬁndings obtained in other cellularmodels (HEK293 cells overexpressing
HCN2 or HL-1 cells [16,17]). In addition, our data reveal direct interac-
tions between S-LPS (but not R595) and cardiac HCN channels, namely
HCN2 (the predominant isoform in human atrial myocytes [37]) and
HCN4 (the prevalent isoform in sinoatrial node cells [38]). However,
the exact binding site(s) of S-LPS to the respectiveHCN channels remain
to be explored.
HCN4 is considered as themain isoform contributing to the sinoatri-
al pacemaking process [13]. Thus, binding of S-LPS to HCN4 most likely
accounts for If impairment in murine sinoatrial node cells [16] and may
contribute to reduction of beating rate in spontaneously active murine
HL-1 cells [17].Pacemaker channelsmay also be indirectly affected by inﬂammatory
cytokines (e.g. TNFα) released in response to bacterial and viral infec-
tions. Cytokines have been reported to play a pivotal role in gram-
negative sepsis, particularly inmyocardial dysfunction [43,44], probably
by causing alterations in calcium homeostasis and production of nitric
oxide (NO). The latter has been shown tomodulate a number of cardiac
ionic currents [45,46] including the sinoatrial pacemaker current [47]
which can be stimulated by NO. This stimulation may partly contribute
to sinus tachycardia in septic shock. Similar cascades are evoked by
gram-positive sepsis which also may modulate pacemaker channel ac-
tivity and hence heart rate [48,49]. Furthermore, inﬂammatory cyto-
kines (interferons) released in response to viral brain infections have
been reported to inhibit neuronal pacemaker channel activity [50].
Taken together, cytokine-dependent modulations of pacemaker chan-
nels provide a further cellularmechanism to alter sinoatrial pacemaking
as well as neuronal network oscillations.
Ivabradine blocks If in cardiomyocytes including both human atrial
[37] and rabbit sinoatrial node cells [20] aswell as HCN4 overexpressing
CHO cells [51]. We also observed If reduction (approx. 66%) by 1 μmol/L
ivabradine (atmembrane potentials from−80 to−130mV), a concen-
tration which has no effects on other membrane currents [20,52].
Under septic conditions, If block by ivabradine is signiﬁcantly atten-
uated. If blocking capacity in the presence of S-LPS is paralleled by
Fig. 6. Effect of ivabradine on If characteristics in human atrialmyocytes under septic conditions. Cells were incubatedwith endotoxins (10 μg/mL, 6–10 h) and superfusedwith ivabradine
(1 μmol/L, 7 min). Mean I–V relationships of If in S-LPS (A) or R595 incubated cells (B) before and after ivabradine superfusion. (C) Use-dependent development of ivabradine blockage of
If. Currents were elicited by hyperpolarizing voltage steps to−100 mV (3 s duration) at 1/6 Hz. (D). Percentage of If reduction by ivabradine was calculated from the underlying I–V
relationships before and after ivabradine perfusion. ‡p ≤ 0.05 vs. S-LPS; §p ≤ 0.05 vs. R595; *p ≤ 0.05 vs. control; #p ≤ 0.05 vs. ivabradine.
Ex Wavelength: 283 nm
Em Wavelength: 328 nm
Fig. 7. Intracellular ivabradine concentrations in guinea pig ventricular myocytes under septic conditions. Untreated (controls) and endotoxin-treated (S-LPS or R595, 10 μg/mL, 6 h) cells
were incubatedwith ivabradine (1 μmol/L, 15 min). (A) Representative HPLC-chromatograms for intracellular ivabradine content in control and S-LPS treated cells. (B) Percentage change
of intracellular ivabradine concentrations in S-LPS and R595 incubated cells compared to respective controls. *p ≤ 0.05 vs. control.
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Fig. 8. Effects of S-LPS and ivabradine on pacemaker activity of a sinoatrial cell model. A rabbit sinoatrial pacemaker cellmodel was used to investigate S-LPS-induced V1/2 shift of−14mV
and ivabradine-induced If reduction (66% and 35% in control and S-LPS-treated cells, respectively). (A) I–V relationships of If using the computational model: If was voltage clamped from
−40 to−140mV in 10mV steps of 3 s duration for indicated conditions (1) control, (2) ivabradine, (3) S-LPS, (4) S-LPS and ivabradine. (B) Time course of spontaneous action potentials
computed for indicated conditions (1) to (4). (C) Changes in cycle length (CL) are represented as a function of (i) reduction in If conductance (If scaling factor) and (ii) If–V1/2 shift to more
negative membrane potentials. The arrows indicate the speciﬁc parameter setting (1) to (4).
71S. Scheruebel et al. / Journal of Molecular and Cellular Cardiology 72 (2014) 64–73reduced intracellular ivabradine concentrations. As a consequence, less
ivabradine is likely to be available for binding to the inner channel pore.
Moreover, an altered access and/or binding behaviour of ivabradine due
to S-LPS–HCN interaction might further inﬂuence ivabradine's blocking
potency. None of these mechanisms are likely to occur for R595 treat-
ment since this LPS-form did not alter intracellular ivabradine concen-
tration or interact with the HCN channels. The exact mechanism how
R595modulates action of ivabradine on If remains to be further investi-
gated. It is worth mentioning that the susceptibility of gram-negative
bacteria towards hydrophobic agents also depends on the LPS-form on
their surface [53]. For example, in case of deep-rough Re-LPS mutant
strains, hydrophobic antibiotics such as macrolides readily access the
cell surface and permeate into the cell interior through the lipid bilayer,
while no accumulation was observed in strains having S-LPS [54].
Therefore, one may speculate that incorporation of S-LPS in human
myocytes hinders the accumulation and transfer of the hydrophobic
ivabradine.
Our data show that in the presence of S-LPS, If current densities are
reduced at physiologically relevant membrane potentials. Therefore,
the question arises whether a decreased If as found under septic condi-
tions is still a suitable target for ivabradine in order to reduce sinoatrial
beating rate. It is known that during the diastolic depolarization phase
of the sinoatrial action potential, very small net inward currents aresufﬁcient to depolarize the cell membrane towards the action potential
threshold [55]. Since If of mammalian sinoatrial [16] and human atrial
myocytes is impaired by S-LPS in a similar manner and the inhibitory
effect of ivabradine on human atrial If is comparable to that on sinoatrial
mammalian If [37], we implemented our experimental data into a sino-
atrial cell model. This in silico approach suggests that ivabradine should
still be capable of decreasing sinoatrial beating rate under septic condi-
tions through If inhibition. Nevertheless, it has to be mentioned that si-
noatrial pacemaking in vivo is a very complex process due to the close
interaction of themembrane clock (cyclic opening and closing of mem-
brane ion channels) and the calcium clock (rhythmic spontaneous Ca2+
release from the sarcoplasmatic reticulum) [56]. Furthermore, the data
presented in this study are gained from quiescent atrial myocytes,
which exhibit differences in ion channel expression and hence electro-
physiological characteristics. These differences might inﬂuence experi-
mental outcome. Therefore further investigations using spontaneously
active cardiomyocytes are required to conﬁrm our conclusions and to
get a deeper insight in the effect of ivabradine on heart rate under septic
conditions in vivo. Such studies are of special interest since currently the
clinical MODIfY trial studies the beneﬁts of heart rate reduction by
ivabradine in patients suffering from MODS [19], where heart rate is
usually elevated due to increased oxygen demand and cytokine levels
[57] and has been proved to predict survival [3,58]. Pure heart rate
72 S. Scheruebel et al. / Journal of Molecular and Cellular Cardiology 72 (2014) 64–73reduction by ivabradine could therefore improve the outcome of
patients in shock by lowering myocardial oxygen demand, improving
diastolic coronary perfusion and acting on the negative force-frequency
relationship of the failing heart [57].
In summary, our data demonstrate for the ﬁrst time that O-chain-
dependent interaction of endotoxin to HCN channels mediates If reduc-
tion under septic conditions. Even though If blocking capacity of
ivabradine is reduced under elevated endotoxin levels in vitro, this
drug is effective to decelerate sinoatrial beating rate in the presence of
S-LPS in silico. Thus, the medical application of ivabradine as a heart
rate reducing agent in critically ill patients (during MODS and sepsis)
might favor a better therapeutic outcome.
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